Mineralys Therapeutics, Inc.(MLYS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MLYS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Mineralys Therapeutics, Inc. (MLYS), a Healthcare sector company. MLYS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Mineralys Therapeutics, Inc. reports net income of $-39.3M, free cash flow of $-39.5M. Top institutional holders of MLYS by reported 13-F value include Catalys Pacific,, RA CAPITAL MANAGEMENT, L.P., Samsara BioCapital,, based on the most recent SEC filings. MLYS trades on the Nasdaq exchange and files with the SEC under CIK 1933414. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MLYS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Mineralys Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-39.3M
Free Cash Flow
Q1 2026
$-39.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
Operating Income
EPS (Diluted)
Total Assets
Op. Cash Flow
| Metric | FY 2025 | FY 2021 |
|---|---|---|
| Net Income | $-154.7M | — |
| Operating Income | $-170.6M | — |
| EPS (Diluted) | $-2.29 | — |
| Total Assets | $661.8M | — |
| Operating Cash Flow | $-142.4M | — |
AI Insight: MLYS Financial Trends
Quarterly cash burn moderating — net loss narrowed to $32M in Q4 2025, the lowest in the observed period, before ticking back up to $39M in Q1 2026.
• Net loss peaked at $56M in Q3 2024 then trended lower, reaching $32M in Q4 2025 — a 43% reduction over five quarters.
• Equity base more than doubled from $237M in Q3 2024 to $647M in Q4 2025, reflecting capital raises that extend the cash runway.
• Operating cash outflow moderated from a peak of $67M in Q4 2024 to $29M in Q3 2025, though it re-accelerated to $39M in Q1 2026.
⚠ Net loss and operating cash burn both re-widened in Q1 2026 after hitting cycle lows in Q4 2025 — potential reversal of the improvement trend.
⚠ Zero revenue across all eight quarters; burn rate sustainability depends entirely on future capital raises or a commercial milestone.
AI Insight: MLYS Ratio Trends
Return metrics have improved sharply from Q4 2024 lows but ticked slightly wider in Q1 2026, signaling a pre-revenue biotech still burning cash at a moderating pace.
• ROE improved dramatically from -102.4% in Q4 2024 to -19.9% in Q4 2025, before widening slightly to -24.7% in Q1 2026.
• ROIC followed a similar path, recovering from -62.3% in Q2 2024 to -23.7% in Q4 2025, then edging back to -28.4% in Q1 2026.
• OpMargin and NPM are absent across all periods, consistent with a clinical-stage company generating no product revenue.
⚠ ROE, ROA, and ROIC all widened in Q1 2026 vs. Q4 2025 — first sequential deterioration after four consecutive quarters of improvement.
⚠ D/E data is entirely missing; leverage structure and runway cannot be assessed from available ratios alone.
Get alerted when MLYS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Mineralys Therapeutics, Inc. including:
Top Institutional Holders of MLYS
Catalys Pacific, LLC
$214.1M7,903,838 shRA CAPITAL MANAGEMENT, L.P.
$208.4M7,692,750 shSamsara BioCapital, LLC
$159.0M5,871,018 shFMR LLC
$131.7M4,861,104 shBlackRock, Inc.
$121.4M4,481,582 shWELLINGTON MANAGEMENT GROUP LLP
$91.0M3,359,068 shSTATE STREET CORP
$79.5M2,935,940 shCaligan Partners LP
$75.1M2,772,654 shVANGUARD CAPITAL MANAGEMENT LLC
$66.5M2,454,363 shLaurion Capital Management LP
$60.5M2,232,040 sh
| Fund | Value | Shares |
|---|---|---|
| Catalys Pacific, LLC | $214.1M | 7,903,838 |
| RA CAPITAL MANAGEMENT, L.P. | $208.4M | 7,692,750 |
| Samsara BioCapital, LLC | $159.0M | 5,871,018 |
| FMR LLC | $131.7M | 4,861,104 |
| BlackRock, Inc. | $121.4M | 4,481,582 |
| WELLINGTON MANAGEMENT GROUP LLP | $91.0M | 3,359,068 |
| STATE STREET CORP | $79.5M | 2,935,940 |
| Caligan Partners LP | $75.1M | 2,772,654 |
| VANGUARD CAPITAL MANAGEMENT LLC | $66.5M | 2,454,363 |
| Laurion Capital Management LP | $60.5M | 2,232,040 |
More Healthcare Companies
View all Healthcare →Put MLYS on your watchlist
Track score changes the day Mineralys Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MLYS a good stock to buy?
13F Pro's AI-powered analysis of Mineralys Therapeutics, Inc. (MLYS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MLYS are available on the MLYS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MLYS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MLYS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Mineralys Therapeutics, Inc.'s investment landscape.